Cipla to invest ZAR 900 million in equity share capital of South Africa subsidiary

The investment will be utilised to reduce inter-group debt and improve the capital structure of CMSA and its subsidiaries.

The transaction is expected to be completed on or before 28th February 2025 or such other date mutually agreed between the parties.

Medical Dialogues team had earlier reported that Cipla Limited had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India.

Read also: Cipla elevates Achin Gupta as new Global Chief Operating Officer

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.

Read also: Cipla Global Chief Manufacturing Officer Rajeev Kumar Sinha resigns